RAF1 and cancer: A combination of tyrosine kinase & C-Raf inhibitor, Sorafenib and vorinostat is currently being studied in the treatment of advanced cancers[35], but we could not find any studies performed using a combination of B-raf inhibitors and vorinostat or romidepsin.